Easing the Economic and Clinical Burden of Psoriasis and Psoriatic Arthritis: The Role of Managed Care

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety and efficacy findings.

August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving quality of life in patients with moderate to severe scalp psoriasis.

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to severe psoriasis across 2 studies.

Both drugs showed significant improvements, with higher response observed for bimekizumab, study finds.

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival challenges.